Dual CD22/CD19 CAR-T Produces Durable Remissions in B-ALL
A peer reviewed Blood Cancer Discovery study reported that all 11 adults and children with relapsed or refractory B cell acute lymphoblastic leukemia achieved complete remission by Day 28 after CART2219.1, and 91 percent…
